Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France
C Bergeron, N Largeron, R McAllister… - International journal of …, 2008 - cambridge.org
Objectives: A vaccine to prevent diseases due to human papillomavirus (HPV) types 6, 11,
16, and 18 is now available in France. The objective of this study was to assess the health …
16, and 18 is now available in France. The objective of this study was to assess the health …
Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients
J Slavinsky Iii, P Kissinger, L Burger… - … journal of STD & …, 2001 - journals.sagepub.com
Human papillomaviruses (HPV) infecting the genital tract are associated with warts and
anogenital malignancies. Although HPV is a highly prevalent sexually transmitted disease …
anogenital malignancies. Although HPV is a highly prevalent sexually transmitted disease …
[HTML][HTML] Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
B Serrano, L Alemany, S Tous, L Bruni… - Infectious agents and …, 2012 - Springer
Background Information on human papillomavirus (HPV) type distribution is necessary to
evaluate the potential impact of current and future HPV vaccines. We estimated the relative …
evaluate the potential impact of current and future HPV vaccines. We estimated the relative …
Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model–based analysis
N Van de Velde, MC Boily, M Drolet… - Journal of the …, 2012 - academic.oup.com
Background Bivalent and quadrivalent human papillomavirus (HPV) vaccines are now
licensed in several countries. Furthermore, clinical trials examining the efficacy of a …
licensed in several countries. Furthermore, clinical trials examining the efficacy of a …